Order Article Reprints

Chuma M, Uojima H, Numata K, Hidaka H, Toyoda H, Hiraoka A, Tada T, Hirose S, Atsukawa M, Itokawa N, et al. Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma. Cancers. 2020; 12(2):293. https://doi.org/10.3390/cancers12020293

Chuma, Makoto, Haruki Uojima, Kazushi Numata, Hisashi Hidaka, Hidenori Toyoda, Atsushi Hiraoka, Toshifumi Tada, Shunji Hirose, Masanori Atsukawa, Norio Itokawa, and et al. 2020. "Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma" Cancers 12, no. 2: 293. https://doi.org/10.3390/cancers12020293

Chuma, M., Uojima, H., Numata, K., Hidaka, H., Toyoda, H., Hiraoka, A., Tada, T., Hirose, S., Atsukawa, M., Itokawa, N., Arai, T., Kako, M., Nakazawa, T., Wada, N., Iwasaki, S., Miura, Y., Hishiki, S., Nishigori, S., Morimoto, M., ... Maeda, S. (2020). Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma. Cancers, 12(2), 293. https://doi.org/10.3390/cancers12020293